Navigation Links
Immune Targeting Systems Completes Second Tranche of Series-A Funding Bringing Total Funds Raised to More Than GBP5m
Date:1/28/2009

LONDON, January 28 /PRNewswire/ -- Immune Targeting Systems (ITS) Limited, a company developing synthetic vaccines for mutating viruses, today announced it has received GBP2.4m of investment as the second tranche of its series-A funding round. ITS's investors HealthCap, the London Technology Fund, Novartis Venture Fund & Truffle Capital provided additional funding to enable a seamless transition into the clinic for the company's universal flu vaccine program which has now entered the GMP pre-clinical phase.

Simultaneously ITS has moved to strengthen its board and management team with the appointment of Brenda Reynolds, a co-founder of PowderMed (acquired by Pfizer in 2006), as company director. Another seasoned vaccine industry professional, Jill Makin, former VP of R&D for Emergent Biosolutions and Microscience, also joins in a consultancy capacity and is responsible for the GMP vaccine manufacture and its release to the clinic.

ITS CEO Carlton Brown commented: "Brenda and Jill are valuable additions to the team and will help drive both our clinical and commercial programs forward. The second tranche of investment brings our total funding to more than GBP5m, including a GBP0.5m development grant from the London Development Agency. We are aiming to raise series-B investment in 2009 to fund our universal influenza vaccine clinical program to proof-of-concept and bring other prioritized candidates through the pipeline. We expect to commence the clinical program by the end of 2009. Despite the current economic climate, our research tells us that the market remains strong for both a successful universal influenza vaccine and therapeutic T-cell vaccine platform."

    Corporate Inquiries
    Carlton Brown; Chief Executive Officer
    Tel +44-7970-944-454, +44-20-7691-4908
    Email: carlton.brown@its-innovation.co.uk


'/>"/>
SOURCE Immune Targeting Systems (ITS) Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Innovative Beverage Products Launches New Product Designed to Enhance the Bodys Immune Defense
2. Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimers Disease Drug Development
3. MedImmune Advances Asthma Program With Start of Phase 2 Clinical Trial for Antibody Targeting IL-5 Receptor
4. Advances in Detection Technology Drive the European Autoimmune Disease Diagnostics Market
5. IDRI and Immune Design Corp. Enter License Agreement on GLA Vaccine Adjuvant
6. MedImmune Announces Zook as President
7. AutoImmune Inc. Reports 2008 Third Quarter Financial Results
8. Visualizing asthma-causing immune cells at work
9. Protein-printing technique gives snapshots of immune system defense
10. Peptimmune Presentations at Upcoming Events
11. MedImmune Presents Data Highlighting its Progressive Inflammatory Disease Portfolio at the 72nd Annual Meeting of the American College of Rheumatology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... MARIETTA, Ga. , Aug. 3, 2015  MiMedx ... medicine company utilizing human amniotic tissue and patent-protected processes ... the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic ... will present at the 35 th Annual Canaccord|Genuity ...  Parker H. "Pete" Petit, Chairman and CEO, William ...
(Date:8/3/2015)... Delaware , August 3, 2015 ... in the commercialization of its Bio-electrical Signal Therapy device ... noninvasive treatment of hard to heal chronic wounds, today ... agreement with Chemipal, an Israeli distributor specializing in medical ... device. Chemipal is a 70 years old, ...
(Date:7/31/2015)... VEGAS , July 31, 2015 ... seek resources that help them drive positive health ... a vital source of patient care in their ... annual tradeshow and conference, AmerisourceBergen announced a ... its Pharmacy Services Administration Organization and help independent ...
(Date:7/30/2015)... 2015 AACC welcomed thousands of medical ... Annual Meeting & Clinical Lab Expo in ... meeting showcased revolutionary advancements in clinical testing technology ... providers to diagnose patients quickly and accurately and ... As of Wednesday, July 29, more ...
Breaking Biology Technology:MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 2Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 3Innovative Research on Cancer, Heart Disease, and Infectious Diseases Draws More than 17,500 Attendees to 2015 AACC Annual Meeting 4
... created by researchers at Canada,s National Institute for Nanotechnology ... level of control over individual electrons, a development that ... of a single atom of silicon and measuring less ... quantum dots ever created. , Quantum dots ...
... Topical Gel Provides Ease, Efficacy and Excellent TolerabilityCORONA, Calif., ... WPI ), a leader in generic and specialty branded ... Administration (FDA) has approved GELNIQUE(TM) (oxybutynin chloride) Gel 10%, ... of overactive bladder (OAB) with symptoms of urge urinary ...
... ROI Opportunity for Consumers in Shortest Period of ... examines the potential investment in targeted therapies that ... new report released today by the Deloitte Center ... adoption of personalized medicine to produce a positive ...
Cached Biology Technology:Smallest ever quantum dots bring real world applications closer 2Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 2Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 3Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder 4Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 2Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 3Adoption of Personalized Medicine May Yield Significant ROI; Time to Achieve Benefit Varies Among U.S. Health Care Stakeholders, According to Deloitte Report 4
(Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
(Date:7/30/2015)... Calif. , July 30, 2015 ... services for gene function analysis and biomarker discovery, ... RNA (sgRNA) Knockout Library targeting all human protein ... and permanently "knock out" a gene,s function. Cellecta,s ... a high throughput screening tool so that researchers ...
(Date:7/27/2015)... , July 27, 2015   Zynx Health ... experience-based clinical improvement solutions, today announced that its ... now available on Android smartphones and tablets. With ... post-care organizations can use ZynxCarebook to securely exchange ... condition, streamline care transitions to other care settings, ...
Breaking Biology News(10 mins):NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... the Southeastern Branch of the Entomological Society of ... at the Hilton Baton Rouge (201 Lafayette Street) ... Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, ... citrus greening disease, invasive species, rice and cotton ...
... The onset of Post-Traumatic Stress Disorder (PTSD) is unpredictable. ... events, it is difficult to identify preventative or causative ... developed PTSD to study the disorder, but that means ... to experiencing trauma. Now, through a combination ...
... Silicon, the material of high-tech devices from computer chips to ... applications. The coating "passivates" the material, tying up loose atomic ... But this passivation process consumes a lot of heat and ... that can be added to the devices. Now a ...
Cached Biology News:Gene associated with high anxiety can have protective effect on the battlefield 2Gene associated with high anxiety can have protective effect on the battlefield 3A cooler way to protect silicon surfaces 2A cooler way to protect silicon surfaces 3